Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of liver cancer called hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)
- People whose doctors have recommended, or who have already received, one of these liver cancer treatments: trans-arterial embolization (TAE), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), or drug-eluting beads chemoembolization (DEB-TACE)
- People aged 18 or older
- People who are able to give their informed consent to take part in the trial
Who may not be able to join:
- People who have abnormal blood vessel connections in the gut area (between gastrointestinal arteries) that cannot be treated with embolization (confirm with trial site)
- People whose cancer has spread to parts of the body outside the liver
- People who have liver failure
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Cristina Mosconi, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phone: 0039 3498496325
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Type and size of the injury; Radiological response to therapy; Post treatment complications
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.